Intraneural injection of VEGF165 plasmid gene therapy (Neovasculgen) for nerve regeneration
Peripheral Nerve Injury
Enrolment: 45 · Results not recorded
Loading the evidence…
Biologic
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Peripheral Nerve Injury
Enrolment: 45 · Results not recorded
Lower Limb Ischemia
Enrolment: 210 · Results not recorded
Severe Lower Limb Ischemia
Enrolment: 386 · Results not recorded
Diabetic Foot Ulcer
Enrolment: 144 · Results not recorded
Interstitial Cystitis · Bladder Pain Syndrome
Enrolment: 180 · Results not recorded
Hunner Type Interstitial Cystitis
Enrolment: 180 · Results not recorded
Peripheral Arterial Disease
Enrolment: 100 · Results not recorded
Secondary Raynaud's Phenomenon
Enrolment: 30 · Results not recorded
Diabetic Foot Ulcers
Enrolment: 35 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Traumatic contusive spinal cord injury
VEGF165 increased early tissue sparing and oligodendrogenesis but the benefit was not maintained chronically and allodynia incidence increased.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.